Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-03-03
2009-08-25
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252020, C514S252030, C514S252010, C514S252050, C544S224000, C544S238000
Reexamination Certificate
active
07579350
ABSTRACT:
Functionalized pyridazine derivatives having a low molecular weight and pharmaceutical compositions thereof are useful as alpha-helix mimetics and for treating conditions and/or disorders mediated by alpha-helix-binding receptors and proteins.
REFERENCES:
patent: 56005480 (1981-10-01), None
Wolff Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1” John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al. “Modern Pharmaceutices, 3ed.” Marcel Dekker, New York, 1996, pp. 451 and 596.
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Englsih Translation of JP56005480.
Boger, et al., “Preparation and Diels-Alder Reaction of a Reactive, Electron-Deficient Heterocyclic Azadiene: Dimethyl 1,2,4,5-Tetrazine-3,6-Dicarboxylate. 1,2-Diazine (Dimethyl 4-Phenyl-1,2-Diazine-3,6-Dicarboxylate) and Pyrrole (Dimethyl 3-Phenylpyrrole-2,5-dicarboxylate) Introduction”,Org. Synth. 70: 79-88 (1992).
Rubin, et al., “The cell cycle and cell death”,Curr. Biol. 3: 391-394 (1993).
Sattler, et al., “Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis”,Science 275: 983-986 (1997).
Chao, et al., “BCL-2 Family: Regulators of Cell Death”,Annu. Rev. Immunol. 16: 395-419 (1998).
Branchek, et al., “Molecular Biology and Pharmacology of Galanin Receptors”,Annals N.Y. Acad. Sci. 863: 94-107 (1998).
Chin, et al., “Design and Evolution of a Miniature Bcl-2 Binding Protein”,Angew. Chem. Int. Ed. 40: 3806-3809 (2001).
Hamuro, et al., “Functionalized Oligoanthranilamides: Modular and Conformationally Controlled Scaffords”,Bioorg. Med. Chem. 9: 2355-2363 (2001).
Ernst, et al., “Design of a Protein Surface Antagonist Based on α-Helix Mimicry: Inhibition of gp41 Assembly and Viral Fusion”,Angew. Chem. Int. Ed. 41: 278-281 (2002).
Kutzki, et al., “Development of a Potent Bcl-xLAntagonist Based on α-Helix Mimicry”,J. Am. Chem. Soc. 124: 11838-11839 (2002).
Ernst, et al., “Design and Application of an α-Helix-Mimetic Scaffold Based on an Oligoamide-Foldamer Strategy: Antagonism of the Bak BH3/Bcl-xLComplex”,Angew. Chem. Int. Ed. 42: 535-539 (2003).
Kim, et al., “Therapeutic Potential of Antisense Bcl-2 as a Chemosensitizer for Cancer Therapy”,Cancer 101: 2491-2502 (2004).
Biros Shannon
Gu Shen
Rebek, Jr. Julius
Habte Kahsay T
The Scripps Research Institute
Townsend and Townsend / and Crew LLP
LandOfFree
Scaffolds for α-helix mimicry does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Scaffolds for α-helix mimicry, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Scaffolds for α-helix mimicry will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4107113